Description

This issue of Vital Signs, released on June 12, 2006, provides a strategic overview of the potential impact of patent expirations of blockbuster drugs and the resulting growth opportunity for generic drugs. Additionally, an emerging company profile is provided on Cell Genesys, a biotechnology company focused on the development and commercialization of cancer therapies. Reimbursement and regulatory news from the FDA and CMS are also provided for the week of May 30 - June 2, 2006.